GlassScriptPhysician profile
Chika V Achebe
NPI 1225454275
$8,193.39
in general payments reported to CMS, 2019-2025
26 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,272 · 2022: $1,735 · 2023: $1,813 · 2024: $1,716 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,186.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.29 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,324.71 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $936.60 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $634.53 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $540.71 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $319.42 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $279.35 | 2021-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $254.73 | 2021-2022 | |
| Corium, LLC | $252.11 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $233.12 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $229.41 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $211.85 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $194.09 | 2021-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $188.48 | 2023 | Spravato |
| Tris Pharma INC | $172.85 | 2023-2024 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $162.20 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $155.31 | 2023-2024 | Quviviq |
| Eisai INC. | $135.69 | 2021 | |
| Vanda Pharmaceuticals INC. | $119.64 | 2022-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $82.40 | 2024 | Xelstrym |
| Adlon Therapeutics L.P. | $67.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.03 | 2024-2025 | Cobenfy |
| Indivior INC. | $48.02 | 2022-2024 | Perseris |
| Exact Sciences Corporation | $27.58 | 2024 | Cologuard Collection Kit |
| Tempus Ai, INC | $22.43 | 2024 | |
| Jazz Pharmaceuticals INC. | $16.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chika Achebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.